Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737000 | 0.94 | CACNA1H (0.54) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL3524057 | 0.90 | DRD2 (0.66) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL829444 | 0.89 | DRD2 (0.58) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL31465614 | 0.88 | DRD2 (0.58) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL8254760 | 0.87 | DRD2 (0.64) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL904074 | 0.87 | TDP1 (0.66) | TDP1MEN1GAAKMT2ACHRM2 | |
| SCHEMBL29263630 | 0.86 | DRD2 (0.62) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL826329 | 0.85 | TDP1 (0.69) | TDP1MEN1GAAKMT2ACHRM2 | |
| SCHEMBL826376 | 0.85 | TDP1 (0.69) | TDP1MEN1GAAKMT2ACHRM2 | |
| SCHEMBL22276602 | 0.85 | TDP1 (0.69) | TDP1MEN1GAAKMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1789049-A4 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1789049-A2 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023617-A2 | CYCLIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | HCN4, CACNA1B, SCN5A | DRD2 1834/4885SIGMAR1 963/4885TDP1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.